Time To Antipsychotic Discontinuation After Remission Among Patients With Major Depressive Disorder With Psychotic Features At Tikur Anbessa Specialized Hospital: A Cross-Sectional Study.
| dc.contributor.advisor | Dr. Getahun Belay | |
| dc.contributor.advisor | Professor Solomon Teferra | |
| dc.contributor.author | Assamin Assafaw | |
| dc.date.accessioned | 2026-11-13T13:12:32Z | |
| dc.date.available | 2026-11-13T13:12:32Z | |
| dc.date.issued | 2026 | |
| dc.description.abstract | Background: Major depressive disorder with psychotic features is a severe and disabling condition that requires both antidepressant and antipsychotic treatment. Most international guidelines recommend maintaining antipsychotics for 4-6 months after clinical remission, but data on actual duration and discontinuation practices in our setting is limited for major depressive disorder with psychotic feature treatment. Objective: The objective of this study is to determine the time to antipsychotic discontinuation after remission among patients with major depressive disorder with psychotic features at Tikur Anbessa Specialized Hospital, 2025. Methods: A retrospective cross-sectional study was conducted among cases with major depressive disorder at TASH who had a follow-up for the past 5 years. Census method was used to select eligible patient records from the psychiatry follow-up EMR registry. Data on demographics, clinical profiles, antipsychotic treatment duration, remission, and discontinuation status was collected. Descriptive statistics was used to summarize the data and chi-square test to measure the association between categorical variables and results were presented using tables, graphs and charts. Result: A total of 234 MDD patients were included in the study with a mean (±SD) age of 39.6 ± 14.6 years, of whom 60 (25.6%) had MDD with psychotic features, and 62 (60 MDD-PF + 2 MDD as augmentation) patients initiated antipsychotic treatment, with risperidone, 58.3% and olanzapine, 25% being the most commonly prescribed. Clinical remission was achieved in 56.4% patients receiving antipsychotics. Prolonged antipsychotic treatment was found in 65.7% patient, and 48.6% patients still continued antipsychotic treatment following remission for a mean duration of 16.2 months (median: 15.5 months, IQR:9.4 months). Comorbid medical illness was the only factor significantly associated with remission (p = 0.011). Conclusion: The findings provide evidence on rational antipsychotics use and treatment practices for patients with major depressive disorder with psychotic features who start treatment at tertiary care setting. It supports the need to develop an institutionalized or national treatment protocol; help to improve psychiatric care while Vreducing the unnecessary prolonged antipsychotics use to ease the burden on both patients and the healthcare system | |
| dc.identifier.uri | https://etd.aau.edu.et/handle/123456789/9602 | |
| dc.language.iso | en | |
| dc.publisher | Addis Ababa Uinverstiy | |
| dc.subject | Major depressive disorder | |
| dc.subject | Psychotic features | |
| dc.subject | Time to antipsychotic discontinuation | |
| dc.subject | clinical remission | |
| dc.subject | Ethiopia. | |
| dc.title | Time To Antipsychotic Discontinuation After Remission Among Patients With Major Depressive Disorder With Psychotic Features At Tikur Anbessa Specialized Hospital: A Cross-Sectional Study. | |
| dc.type | Thesis |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed to upon submission
- Description: